# Daily Iteration Report — 2026-08-13 (Thursday)

## Work queue items completed (5)

1. **Gap #12 audit** (Treg/CAR-T × Diabetic Neuropathy, was overdue 2026-08-09) → **REMAINS SILVER.**
   No CAR-Treg/Treg intervention trial exists for diabetic peripheral neuropathy. Current CAR-Treg
   landscape (autoCD6-CAR Treg, ABA-201) targets T1D beta-cell autoimmunity. New adjacent (non-Treg)
   DPN cell-therapy trial found: NCT07183761 (umbilical-cord MSC for moderate–severe DPN, recruiting,
   start Oct-2025). Biological plausibility unchanged; no promotion. Next audit ~2026-09-13.

2. **Gap #4 audit** (Islet Transplant × Personalized Nutrition, was overdue 2026-08-09) → **REMAINS SILVER.**
   No genomic/microbiome-driven personalized-nutrition intervention for islet-graft outcomes. 2026 field
   remains encapsulation / HIP-modified stem-cell islets (Sana SC451 IND ~2026) / long-term graft-survival
   cohorts. Post-transplant nutrition still generic. No promotion.

3. **Gap #5 audit** (Islet Transplant × Drug Repurposing, due 2026-08-13) → **REMAINS SILVER.**
   Individual repurposed compounds reaffirmed (etanercept/TNF-α blockade, alpha-1 antitrypsin) plus a NEW
   preclinical eIF5A-hypusination inhibitor GC7 (bioRxiv 2025-11-24, DOI 10.1101/2025.11.24.689446,
   cell/rodent only — preprint, not PubMed-indexed, logged as watch, NOT fabricated). Still no systematic
   repurposing *screen* targeting islet-transplant outcomes. No promotion.

4. **Path revalidation** — `oxidative_stress → cardiovascular` (oldest by validated_date, 2026-06-07) →
   **REAFFIRMED VALIDATED (HIGH/HIGH).** 2025 MDPI Antioxidants review (PMC11759781 / PMID 39857406)
   confirms the exact mechanism chain (hyperglycemia → AGE/PKC/polyol/mitochondrial ROS → endothelial
   dysfunction, NO-signaling disruption, vascular inflammation → macro/microvascular CV complications).
   Adjacent 2025 confirm: PMC11717531. No contradicting evidence.

5. **Paper re-vet batch** — 15 oldest papers with empty `last_checked` (PMIDs 35551307 … 39525461)
   re-checked for claim drift; none found. PMID 37366315 (Retatrutide phase 2, NEJM 2023, 24.2% weight
   reduction) externally re-verified against PubMed — title/journal match. All 15 stamped `last_checked` today.

## Credibility sweep (every run) — CLEAN
- No fabricated PMIDs (>42000000) in any `.py`.
- No "zero SAEs" / "zero rejection" phrases. Only "curative" hits are the linter's own regex definitions in `verify_before_deploy.py`.

## Pipeline rebuild
`run_quality_improvements.py` → **all 41 stages [OK].**

## Weekly PubMed sweep
Skipped — runs Mondays only; today is Thursday.

## State
287 papers (274 VETTED / 13 FLAGGED / 0 unvetted). 57 paths, 15 gaps. State + queue saved;
run_history now 120 entries. Backup written: `agent_state.json.bak_2026-08-13`.

## Git
Commit attempted from sandbox. **Push remains BLOCKED** — no GitHub auth in sandbox
(`could not read Username for https://github.com`). All work persists to disk regardless.
User must `git push` from local PowerShell at `C:\Users\justi\OneDrive\Diabetes_Research`.
